A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Andecaliximab (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur; Nivolumab; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 30 Nov 2020 Status changed from completed to discontinued.
- 25 Jan 2020 Results of novel gene expression analysis software used to identify Hallmarks of Cancer associated with clinical benefit following nivolumab treatment presented at the 2020 Gastrointestinal Cancers Symposium
- 04 Nov 2019 Status changed from active, no longer recruiting to completed.